ALB and neoplasm: Remarkably, the research team established that their albumin nanocarriers facilitated controlled drug release, achieving 73% release at a physiological pH of 7.4 and 87% release at a tumor-acidic pH of 5.4 over 72 h, enabling selective therapeutic action in the tumor microenvironment while minimizing systemic exposure (Fig. 4) [81].